Aldeyra and Janssen will team up to advance research of novel immune-modulating drugs for use in treating systemic inflammatory diseases, according to a press release from Aldeyra Therapeutics.
Aldeyra’s first-in-class drug candidate reproxalap, currently under study for treatment of dry eye disease and anterior uveitis, is designed to sequester proinflammatory aldehyde mediators. The research collaboration is intended to advance this anti-inflammatory technology for use in treating autoimmune and other systemic diseases characterized by inflammation, according to the release.
Janssen
Uncategorized